DIRS.INFO The most relevant business & tech news

☆ Factbox-Foreign Nationals Detained in China
▼ + stars: | 2023-10-11 | by ( Oct. | At A.M. | ) www.usnews.com time to read: +2 min

Here are some other high-profile cases of foreign nationals detained in China:YANG HENGJUNThe Australian writer has been detained in China for more than three years, and in 2021 was tried in Beijing on undisclosed national security charges. His arrest coincided with worsening relations between Australia and China and a verdict in his case has been repeatedly delayed. JAPANESE BUSINESSMANA Japanese employee of Astellas Pharma Inc, who has not been identified publicly, was detained in Beijing in March on suspicion of espionage, sending a chill through the Japanese business community in China. The Chinese foreign ministry, when asked last month if the Japanese employee had been arrested, said foreign nationals in China must abide by the country's laws or be prosecuted otherwise. KAI LILi, who is Chinese-American, has been detained in China since 2016.

Persons: Cheng Lei, YANG HENGJUN, Yang, ROBERT SCHELLENBERG, Meng Wanzhou, MARK SWIDAN, Katherine Swidan, KAI LI Li, Harrison Li, Laurie Chen, Don Durfee, Robert Birsel Organizations: Astellas Pharma Inc, Kyodo, Huawei, United, Reuters Locations: BEIJING, Australian, China, Beijing, Australia, United States, Vancouver, Canada, MARK SWIDAN The Texas, United Nations

☆ Foreign nationals detained in China
▼ + stars: | 2023-10-11 | by ( ) www.reuters.com time to read: +2 min

Persons: Cheng Lei, YANG HENGJUN, Yang, ROBERT SCHELLENBERG, Meng Wanzhou, MARK SWIDAN, Katherine Swidan, KAI LI Li, Harrison Li, Laurie Chen, Don Durfee, Robert Birsel Organizations: Astellas Pharma Inc, Kyodo, Huawei, United, Reuters, Thomson Locations: BEIJING, Australian, China, Beijing, Australia, United States, Vancouver, Canada, MARK SWIDAN The Texas, United Nations

☆ Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
▼ + stars: | 2023-05-17 | by ( David Carnevali | ) www.reuters.com time to read: +4 min

Even shares of drug companies that do not have pending deals but are seen by analysts and investors as potential acquisition targets were hit. FTC officials did not respond to a request for comment on whether they planned to challenge any other pharmaceutical acquisitions. "We could see similar challenges to the Pfizer/Seagen deal" BMO analysts wrote in a note, arguing that the FTC could target other major drug companies with the resources to engage in bundling. UNDER THE RADARConversely, investors and analysts are hoping that smaller pharmaceutical acquisitions will continue to fly under the radar of regulators. Reporting by David Carnevali in New York; Editing by Greg Roumeliotis and Jamie FreedOur Standards: The Thomson Reuters Trust Principles.

☆ In China, a Detention and a New Espionage Law Have Businesses Worried
▼ + stars: | 2023-04-28 | by ( Yoko Kubota | Miho Inada | ) www.wsj.com time to read: 1 min

China’s detention of a Japanese executive at Astellas Pharma is one of a string of incidents that have sparked new concerns among foreign companies. Photo: Akio Kon/Bloomberg NewsBEIJING— Hiroshi Nishiyama , a veteran Japanese executive at Astellas Pharma Inc. and a prominent member of his country’s business circle in China, spent late March wrapping up his assignment there and preparing to head home. He never made it. Mr. Nishiyama disappeared on what was supposed to be his last day in China. A few days later, China’s Foreign Ministry said he had been accused of espionage and detained.

☆ Japan will keep calling for China to act responsibly, Kishida says
▼ + stars: | 2023-04-20 | by ( Yukiko Toyoda | ) www.reuters.com time to read: +3 min

TOKYO, April 20 (Reuters) - Japan will keep calling for China to act responsibly on the world stage, Prime Minister Fumio Kishida said on Thursday, a sign of Tokyo's deepening concern about stability in the Taiwan Strait following Beijing's recent military drills. The comments from Kishida, after China conducted drills in the waters off Taiwan earlier this month, highlight Tokyo's growing alarm about the possibility of an attack on nearby Taiwan. Japan would "continue to call on China to take the responsibility it should be taking as a major country on the world stage," Kishida said during a roundtable interview with members of the foreign media. Japan has joined the United States in putting export restrictions on chip-making tools but in doing so avoided mentioning China so as not to antagonise its neighbour. Kishida also said Japan was calling on China to allow for the return of a Japanese executive detained there.

TOKYO/BEIJING, April 2 (Reuters) - Japan's foreign minister Yoshimasa Hayashi said he called on Beijing for the early release of a detained Japanese national during a meeting with Chinese diplomat Qin Gang held on Sunday. The visit comes a week after a spokesperson of Astellas Pharma Inc (4503.T) said its employee was detained in China for unknown reasons. Although Japan and China have their differences, both agreed to restart trilateral talks with South Korea, Hayashi said, calling the agreement "an important achievement" from his meeting with Qin. "We agreed to continue communicating closely on various levels, including the foreign ministerial and leadership levels," Hayashi added. Japanese Prime Minister Fumio Kishida and Chinese President Xi Jinping met on the sidelines of the Asia-Pacific Economic Cooperation (APEC) summit last November, marking the first leadership-level talks in almost three years.

☆ Japan foreign minister Hayashi to visit Beijing on Saturday
▼ + stars: | 2023-03-31 | by ( ) www.reuters.com time to read: +2 min

TOKYO, March 31 (Reuters) - Japan Foreign Minister Yoshimasa Hayashi said on Friday he will visit Beijing for two days from Saturday to discuss a range of issues, including the detention of an Astellas Pharma Inc (4503.T) employee. Hayashi told reporters he will meet with Chinese Foreign Minister Qin Gang during the visit for "an honest and frank discussion to create a constructive and stable relationship". Hayashi's visit to China follows leadership-level talks held on the sidelines of an international summit last November, the first between the two countries in almost three years. At the time, Japanese Prime Minister Fumio Kishida said he conveyed his concerns over China's increasing maritime military presence but also said the two leaders agreed to reopen diplomatic channels of communications including a visit by Japan's foreign minister to China in the near future. Reporting by Sakura Murakami and Rocky Swift; Editing by Shri Navaratnam and Sonali PaulOur Standards: The Thomson Reuters Trust Principles.

☆ Japanese man detained in China is Astellas Pharma employee
▼ + stars: | 2023-03-26 | by ( ) www.reuters.com time to read: +1 min

TOKYO, March 26 (Reuters) - A Japanese man detained in China is an employee of Astellas Pharma Inc (4503.T), a company spokesperson told Reuters on Sunday. The company did not identify the employee and the spokesperson said it was not clear as to why he had been detained. Kyodo and other Japanese media reported on Saturday that a Japanese man in his 50s was taken into custody in Beijing this month for an alleged violation of Chinese law. But China had not fully explained what prompted authorities in Beijing to detain the man, media said. The Japanese government had asked Chinese authorities to release the man, media reported.

☆ US declines to force lower price on cancer drug Xtandi
▼ + stars: | 2023-03-21 | by ( ) www.reuters.com time to read: +2 min

WASHINGTON, March 21 (Reuters) - The U.S. government will not force Pfizer Inc (PFE.N) and Astellas Pharma Inc (4503.T) to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, the National Institutes of Health (NIH) said on Tuesday. Patient group the Union for Affordable Cancer Treatment first filed a petition calling on the NIH to use its authority to lower the drug's price in March 2016. The NIH said in a letter made public on Tuesday that its analyses in response to the petition found the prostate cancer treatment was widely available. "NIH does not believe that use of the march-in authority would be an effective means of lowering the price of the drug," the letter said. Progressive lawmakers in the Democratic Party have been calling on President Joe Biden's administration to use its march-in authority to lower drug prices.

☆ Merck scraps third prostate cancer study as Keytruda therapy disappoints
▼ + stars: | 2023-02-28 | by ( Bhanvi Satija | ) www.reuters.com time to read: +2 min

The setbacks were likely to put Merck further behind in its quest to develop a treatment for advanced forms of the most common cancer type in the United States. It had in January stopped a late-stage study of the drug in some prostate cancer patients. An interim analysis showed the combination therapy did not extend survival or help extend the time a patient lives without the disease worsening compared to placebo, Merck said. Merck was testing its blockbuster immunotherapy in combination with androgen deprivation therapy and Xtandi, made by Pfizer Inc (PFE.N) and Astellas Pharma Inc (4503.T), in patients with an advanced form of treatment-resistant prostate cancer. Additionally, Merck said another combination treatment with Keytruda did not meet the main goal in a separate late-stage study for a type of lung cancer that can spread to other parts of the body.

☆ Merck scraps Keytruda trial for prostate cancer after dismal interim data
▼ + stars: | 2023-01-25 | by ( ) www.reuters.com time to read: +1 min

Jan 25 (Reuters) - Merck & Co Inc (MRK.N) said on Wednesday it was discontinuing a late-stage trial of its blockbuster immunotherapy Keytruda in some prostate cancer patients after interim data showed it was unlikely to meet the study's main goals. The interim analysis showed the therapy did not extend survival or help extend the time a patient lives without the disease worsening, the U.S. drugmaker said. The trial had enrolled 1,251 patients who received the combination therapy with Keytruda or a placebo. Prostate cancer is the most common cancer in the United States with nearly 270,000 new cases and 34,500 deaths in the country in 2022, according to government data estimates. Separately, Merck said Keytruda in combination with a chemotherapy showed significant improvement in overall survival in patients with an advanced type of bile duct cancer.

Search resuls for: "Astellas Pharma Inc"

11 mentions found